Pharsight

Skyla is owned by Bayer Hlthcare.

Skyla contains Levonorgestrel.

Skyla has a total of 5 drug patents out of which 0 drug patents have expired.

Skyla was authorised for market use on 09 January, 2013.

Skyla is available in intrauterine device;intrauterine dosage forms.

Skyla can be used as a method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system, a method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus.

The generics of Skyla are possible to be released after 01 April, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP09736608A	2014-02-12	Actavis Group PTC ehf	Patent maintained as amended
EP09736244A	2013-09-18	Actavis Group PTC EHF	Patent maintained as amended
EP03797325A	2008-12-03	N.V. Organon	Patent maintained as amended

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839	BAYER HLTHCARE	Delivery system and a manufacturing process of a delivery system	Nov, 2023 (5 months from now)
US9615965	BAYER HLTHCARE	Inserter	Sep, 2029 (6 years from now)
US10561524	BAYER HLTHCARE	Inserter	Sep, 2029 (6 years from now)
US10987244	BAYER HLTHCARE	Inserter	Apr, 2031 (7 years from now)
US9668912	BAYER HLTHCARE	Inserter	Apr, 2031 (7 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2013

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE